ArticleScientific reports2026
Molecular dynamics investigation of temozolomide encapsulation and controlled release from PLGA carriers.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Controlled drug delivery remains a key challenge in the treatment of brain cancer. In this study, the encapsulation and release behavior of the anticancer drug temozolomide (TMZ) in poly(lactic-co-glycolic acid) (PLGA) carriers are investigated using molecular dynamics simulations. Key structural and energetic parameters, including mixing energy, hydrogen bonding, and TMZ mobility, are analyzed at loading levels ranging from 10 to 40 wt% of TMZ. The results revealed that increasing TMZ concentration enhanced PLGA-TMZ interactions and resulted in a more compact carrier structures. A loading ratio of 30 wt% of TMZ was identified as providing the optimal balance between stability and release, characterized by favorable hydrogen bonding and mixing energy. The overall drug release rate from the optimal carrier was determined to be 0.0005 ng/s. Furthermore, water infiltration into the polymer matrix, measured at 0.00011 ng/s, was found to cause swelling and create diffusion pathways, which was identified as the dominant release mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.